Research suggests that GLP-1 receptor agonists may be linked to a lower risk of colorectal cancer in patients with inflammatory bowel disease. Some studies also indicate that these agonists may reduce the risk of other cancers, including metastatic cancer progression. The extent of the potential benefits is still being explored, with various outlets reporting on the emerging evidence.